Related Experiment Videos
Cardiac blood-pool scintigraphy using technetium-99m DTPA-HSA: comparison with in vivo technetium-99m RBC labeling
T Nishimura1, S Hamada, K Hayashida
1Department of Radiology, National Cardiovascular Center, Osaka, Japan.
Insights
Technetium-99m diethylenetriaminepentaacetic acid human serum albumin ([99mTc]DTPA-HSA) offers excellent cardiac blood-pool imaging for assessing heart function. This new agent is a safe and effective alternative to conventional methods for cardiac scintigraphy.
Area of Science:
- Nuclear Medicine
- Cardiology
- Radiopharmacology
Background:
- Cardiac blood-pool scintigraphy is crucial for evaluating heart function.
- Conventional methods like 99mTc red blood cell (RBC) labeling have limitations.
- A novel blood-pool agent, [99mTc]DTPA-HSA, was developed for improved cardiac imaging.
Purpose of the Study:
- To evaluate the clinical usefulness of [99mTc]DTPA-HSA in cardiac blood-pool scintigraphy.
- To compare the efficacy of [99mTc]DTPA-HSA with the conventional 99mTc RBC labeling method.
- To assess the safety and diagnostic accuracy of [99mTc]DTPA-HSA for cardiac function assessment.
Main Methods:
- Cardiac blood-pool scintigraphy was performed in 31 patients with heart diseases using [99mTc]DTPA-HSA.
- Biodistribution studies were conducted to compare [99mTc]DTPA-HSA with 99mTc RBC.
- Electrocardiogram (ECG)-gated imaging was used to evaluate left ventricular function, including left ventricular ejection fraction (LVEF).
Main Results:
- Excellent cardiac blood-pool images were obtained with the [99mTc]DTPA-HSA method.
- [99mTc]DTPA-HSA showed higher lung and liver accumulation than 99mTc RBC, but similar blood pool to whole-body count ratios.
- No significant difference in left ventricular target-to-background ratios was observed between the two methods.
- LVEF calculated using [99mTc]DTPA-HSA correlated well with contrast LVEF (r = 0.91).
- No adverse side effects were reported in any patient.
Conclusions:
- Cardiac blood-pool scintigraphy using [99mTc]DTPA-HSA provides high-quality images for cardiac function assessment.
- The [99mTc]DTPA-HSA method is a safe, effective, and readily performed alternative to conventional 99mTc RBC labeling.
- This novel agent is clinically useful for evaluating cardiac function in patients with various heart diseases.
Abstract:
We performed cardiac blood-pool scintigraphy using technetium-99m diethylenetriaminepentaacetic acid human serum albumin [( 99mTc] DTPA-HSA), a newly developed blood-pool agent, in 31 patients with various heart diseases and evaluated its clinical usefulness in comparison with the conventional in vivo 99mTc red blood cell (RBC) labeling. Excellent cardiac blood-pool images were obtained by [99mTc]DTPA-HSA method. Biodistribution studies showed higher accumulation of [99mTc]DTPA-HSA than that of 99mTc RBC in the lungs and liver, but similar count ratios of the cardiovascular blood pool to whole body between the two methods. In ECG-gated end-diastolic images, no quantitatively significant difference was observed in left ventricular target-to-background ratios between these two methods. Left ventricular ejection fraction (LVEF) calculated by [99mTc]DTPA-HSA MUGA method was correlated well with that by contrast LVEF (r = 0.91). No side effects were observed in any patient. In conclusion, cardiac blood-pool scintigraphy using [99mTc] DTPA-HSA is readily performed by single i.v. injection and useful for the assessment of cardiac function.